Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Kelvin Chan , Stephen W Lee Added: 3 years ago
The capabilities of OCT provide cardiologists with an effective tool for the assessment of patients with acute coronary syndrome (ACS), and permit new insights into plaque progression and ruptures. ACS is typically a life-threatening presentation of atherosclerosis. The in-depth lesion evaluation of OCT is invaluable and has enabled the pathophysiology of ACS to be fully unveiled.2 Acute… View more

Imaging & Diagnostics

MI/ACS
Author(s): Didier Carrie , Marco Valgimigli , Gennaro Sardella , et al Added: 3 years ago
Percutaneous coronary intervention (PCI) involving stenting is routine practice, and involves either bare metal stents (BMS) or drug-eluting stents (DES), which allow controlled release of antiproliferative drugs at the arterial waazll.1 However, the persistence of durable polymers in first-generation DES led to numerous problems including inflammation, delayed arterial healing, aneurysm… View more

Intervention
Author(s): Albert Alahmar , Anthony H Gershlick Added: 3 years ago
Drug-eluting stents (DES) have revolutionized the field of interventional cardiology. The US Food and Drug Administration (FDA) is expecting that the total number of DES implanted in 2010 will surpass 5 million worldwide. Although initial results seemed promising, longer-term follow-up in a wider range of patients revealed some concerns. Enhanced platelet aggregation, delayed neointimal growth, a… View more

Intervention
Antithrombotic Therapy after Percutaneous Coronary Intervention
Author(s): Darshni Arishta Jhagroe , Jur ten Berg Added: 3 years ago
Dual antiplatelet therapy (DAPT) is indicated in patients who need to undergo percutaneous coronary intervention (PCI) procedures.1 Compared with oral anticoagulation (OAC) and aspirin, DAPT has been shown to reduce the risk of thrombotic events and the rate of bleeding events.2 Chronic OAC is required in up to 10 % of the patients undergoing PCI, and is usually indicated for AF and mechanical… View more

Anticoagulation

Intervention
Author(s): Eulogio García Fernandez , Didier Carrie , Amadeu Betriu , et al Added: 3 years ago
Drug-eluting stents (DES) have demonstrated their efficacy in reducing restenosis and repeated revascularisation.1–4 Some concerns related to DES safety (increased late stent thrombosis, difficulties with antiplatelet therapy compliance) and cost restrictions have encouraged interventional cardiologists to be selective in the use of DES and bare-metal stents (BMS).5–8 The latest generation of BMS… View more

Imaging & Diagnostics

Intervention
Author(s): Fumiyuki Otsuka , Masataka Nakano , Saami K Yazdani , et al Added: 3 years ago
Percutaneous coronary interventions (PCI) involving stenting are the most widely performed procedures for the treatment of symptomatic coronary disease.1 Although first-generation sirolimus-eluting stents (SES; Cypher™, Cordis Corp., Miami Lakes, FL) and paclitaxel-eluting stents (PES; Taxus™, Boston Scientific, Natick, MA) have radically reduced restenosis,2,3 complications of late (LST) and… View more

MI/ACS

Intervention
Author(s): Christoph Hehrlein Added: 3 years ago
Percutaneous coronary interventions (PCI) for the treatment of coronary artery obstructions are associated with a high rate of restenosis (20–57%) in the first six months after the procedure.1,2 Metallic stenting has significantly improved short-term procedural outcomes and reduced restenosis rates in patients undergoing PCI.3,4 The surgical stent deployment procedure initially involves the… View more

Intervention
Author(s): Junbo Ge Added: 3 years ago
Drug-eluting stents (DES) became available for the treatment of atherosclerotic coronary heart disease about five years ago. The polymer coatings used in the first-generation DES (Cypher™ and Taxus™) were non-biodegradable. Virmani et al. studied autopsy patients and suggested that late stent thrombosis post-DES implantation might be caused by the polymer.1 Recently, using a hierarchical… View more

Intervention
Author(s): Laurent Bonello Added: 3 years ago
Clopidogrel is a key antiplatelet agent that inhibits the second step of platelet aggregation through blockade of the P2Y12-adenosine diphosphate (ADP) receptor.1 Its use has enabled percutaneous coronary intervention (PCI) to expand by dramatically reducing thrombotic complications in acute coronary syndromes (ACSs).2,3 Since the first report by Jaremo et al. of a large inter-individual… View more

Anticoagulation

MI/ACS
AF, Stent and Anticoagulant
Author(s): Balen Abdulrahman , Richard J Jabbour , Nick Curzen Added: 10 months ago

Anticoagulation

Standards & Guidelines